Morgan Stanley Lowers Alnylam Pharmaceuticals (NASDAQ:ALNY) Price Target to $268.00

Alnylam Pharmaceuticals (NASDAQ:ALNY - Get Free Report) had its price objective lowered by equities research analysts at Morgan Stanley from $284.00 to $268.00 in a research note issued to investors on Friday,Benzinga reports. The brokerage presently has an "equal weight" rating on the biopharmaceutical company's stock. Morgan Stanley's price objective indicates a potential upside of 14.86% from the company's previous close.

ALNY has been the subject of several other research reports. Wells Fargo & Company increased their target price on shares of Alnylam Pharmaceuticals from $275.00 to $287.00 and gave the stock an "equal weight" rating in a report on Friday, March 21st. Redburn Atlantic began coverage on Alnylam Pharmaceuticals in a report on Monday, March 31st. They issued a "buy" rating and a $353.00 price objective for the company. Chardan Capital reiterated a "buy" rating and set a $300.00 target price on shares of Alnylam Pharmaceuticals in a report on Friday, March 21st. Bank of America raised their price target on Alnylam Pharmaceuticals from $302.00 to $325.00 and gave the company a "buy" rating in a research note on Friday, March 21st. Finally, Canaccord Genuity Group upped their price objective on Alnylam Pharmaceuticals from $385.00 to $390.00 and gave the stock a "buy" rating in a research note on Friday, March 21st. One analyst has rated the stock with a sell rating, five have assigned a hold rating and twenty-one have given a buy rating to the stock. Based on data from MarketBeat.com, the stock currently has an average rating of "Moderate Buy" and a consensus price target of $315.58.

Remove Ads

Alnylam Pharmaceuticals Stock Up 1.0 %

ALNY stock traded up $2.39 during trading hours on Friday, reaching $233.32. 441,096 shares of the stock were exchanged, compared to its average volume of 865,897. The company has a market cap of $30.35 billion, a price-to-earnings ratio of -107.52 and a beta of 0.30. The firm's 50-day moving average is $251.53 and its 200-day moving average is $257.83. Alnylam Pharmaceuticals has a 12 month low of $141.98 and a 12 month high of $304.39. The company has a debt-to-equity ratio of 15.27, a current ratio of 2.78 and a quick ratio of 2.71.

Alnylam Pharmaceuticals (NASDAQ:ALNY - Get Free Report) last announced its earnings results on Thursday, February 13th. The biopharmaceutical company reported ($0.65) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.62) by ($0.03). On average, equities research analysts expect that Alnylam Pharmaceuticals will post -1.7 earnings per share for the current year.

Insider Activity at Alnylam Pharmaceuticals

In related news, CFO Jeffrey V. Poulton sold 967 shares of the business's stock in a transaction on Friday, February 14th. The stock was sold at an average price of $255.17, for a total transaction of $246,749.39. Following the sale, the chief financial officer now owns 32,786 shares in the company, valued at $8,366,003.62. The trade was a 2.86 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, EVP Kevin Joseph Fitzgerald sold 663 shares of Alnylam Pharmaceuticals stock in a transaction dated Friday, February 14th. The shares were sold at an average price of $255.21, for a total value of $169,204.23. Following the sale, the executive vice president now directly owns 14,321 shares in the company, valued at $3,654,862.41. The trade was a 4.42 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last three months, insiders have sold 71,234 shares of company stock valued at $19,958,097. 1.50% of the stock is owned by insiders.

Hedge Funds Weigh In On Alnylam Pharmaceuticals

Several large investors have recently modified their holdings of ALNY. Larson Financial Group LLC grew its stake in shares of Alnylam Pharmaceuticals by 187.2% in the fourth quarter. Larson Financial Group LLC now owns 112 shares of the biopharmaceutical company's stock worth $26,000 after purchasing an additional 73 shares during the last quarter. Park Square Financial Group LLC acquired a new position in Alnylam Pharmaceuticals during the 4th quarter worth about $28,000. Whipplewood Advisors LLC grew its position in shares of Alnylam Pharmaceuticals by 208.8% in the 1st quarter. Whipplewood Advisors LLC now owns 105 shares of the biopharmaceutical company's stock valued at $28,000 after buying an additional 71 shares during the last quarter. R Squared Ltd acquired a new stake in shares of Alnylam Pharmaceuticals in the fourth quarter valued at about $33,000. Finally, OFI Invest Asset Management bought a new position in shares of Alnylam Pharmaceuticals during the fourth quarter worth about $35,000. Institutional investors own 92.97% of the company's stock.

About Alnylam Pharmaceuticals

Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1.